NCT05307042

Decline in Renal Concentration Ability in Lithium Treated Patients

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 51 (estimated)
• Sponsor: Radboud University Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Lithium therapy is cornerstone in therapy of bipolar disorders. A well known side-effect of lithium therapy is a urinary concentration defect which manifests in it's most severe form as nephrogenic diabetes insipidus. The development of urinary concentration defects and its progression to nephrogenic diabetes insipidus in the population of lithium treated patients is unknown and therefore this study aims to evaluate the decline of urinary concentration defects in a Dutch population of lithium treated patients. In this prospective cohort study, 51 participants treated with lithium at Canisius Wilhelmina Hospital, Nijmegen and included in the previous study in 2012 will be approached to undergo a follow-up dDAVP-test.

Conditions

• Lithium Toxicities
• Bipolar Disorder
• Concentration Ability Impaired
• Nephrogenic Diabetes Insipidus
• Lithium - Induced Nephropathy

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	Deamino Arginine Vasopressin (dDAVP)	After voiding, 40 μg 1-desamino-8-D arginine vasopressin (dDAVP) will be administered intranasally. Throughout the day, urine volume and maximal renal concentrating ability will be determined by measuring osmolality in urine collected at 4 and 6 hours after administration of dDAVP. In addition, water intake, body weight, blood pressure and heart rate will be determined at baseline and 6 hours after administration of dDAVP.

Timeline

• Start date: 2022-05-01
• Primary completion: 2022-12-01
• Completion: 2022-12-01
• First posted: 2022-04-01
• Last updated: 2022-04-01

Locations

1 site across 1 country: Netherlands